Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative
delirium in liver transplant patients in the ICU.
Single center prospective randomized placebo controlled clinical trial 0.1mcg/kg/hr of
dexmedetomidine or equivalent amount of saline infusion started after induction of anesthesia
for liver transplantation and continued until 48 hours after surgery.
Outcomes will be assessed up to 1 week or transfer to ward, whichever comes first.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer